Skip to main content

Table 2 Pharmacokinetics of pembrolizumab at steady state of regimens of 2 mg/kg Q3W, 200 mg Q3W, 10 mg/kg Q3W and 10 mg/kg Q2W. Based on pooled cross-study data [n, Mean (%CV), Median (10-90 percentile)]

From: Evaluation of dosing strategy for pembrolizumab for oncology indications

PK Value (unit) Dose Regimen N Mean (%CV) Median 10–90 Percentile
Cmax
(mcg/mL)
2 mg/kg Q3W 755 68.0 (24%) 66.3 48.3–88.2
200 mg Q3W 830 93.4 (26%) 89.1 66.4–124.3
10 mg/kg Q3W 1403 360.3 (23%) 357.6 257.7–466.8
10 mg/kg Q2W 652 459.3 (25%) 457.7 315.9–599.9
Ctrough
(mcg/mL)
2 mg/kg Q3W 755 22.2 (48%) 21.1 9.18–35.7
200 mg Q3W 830 29.7 (47%) 27.6 14.9–46.2
10 mg/kg Q3W 1403 126.4 (44%) 120.4 59.8–200.2
10 mg/kg Q2W 652 220.9 (39%) 217.8 111.8–325.3
AUCss, 0-6-weeks
(mcg*day/mL)
2 mg/kg Q3W 760 1376.5 (38%) 1316.5 724.9–2038.5
200 mg Q3W 830 1871.1 (37%) 1787.0 1120.6–2730.9
10 mg/kg Q3W 1405 7625.4 (35%) 7436.0 4354.0–11172.8
10 mg/kg Q2W 652 12002.7 (34%) 11993.5 6834.7–16895.5